Drugs and Pacemakers in Patients with Atrial Fibrillation and Heart Failure

  • R. M. Polimeni
  • G. Meduri
  • A. Amato
Conference paper


Atrial fibrillation (AF) is a common arrhythmia: its incidence increases markedly with age and it is frequently associated with heart failure (HF) [1]. In patients with HF the incidence of AF is estimated at between 20% and 40%.HF gives rise to electrophysiologic and hemodynamic changes in atrial tissue that favor the onset and maintenance of atrial fibrillation: sympathetic tone, increased pressure, wall-stretching, and mitral regurgitation. On the other hand, the onset of AF in patients with HF often leads to a marked worsening of the clinical condition of these patients: loss of atrial systole, high and irregular ventricular rate, mitral regurgitation, low coronary and cerebral flow, and so on.


Atrial Fibrillation Mitral Regurgitation Heart Failure Patient Rhythm Control Atrial Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kannel WB, Abbott RD, Savage DD et al (1982) Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306:1018–1022CrossRefGoogle Scholar
  2. 2.
    Goldenberg IF, Lewis WR, Dias VC et al (1994) Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive cardiac failure. Am J Cardiol 74:884–889PubMedCrossRefGoogle Scholar
  3. 3.
    Clemo HF, Wood MA, Gilligan DM et al (1998) Intravenous amiodarone for acute heart rate in critically ill patients with atrial tachyarrhythmias. Am J Cardiol 81:594598Google Scholar
  4. 4.
    Deedwania PC, Singh BN, Ellenbogen FA et al (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 98:2574–2579PubMedCrossRefGoogle Scholar
  5. 5.
    Andersen HR, Nielsen JC, Thomsen PEB, Thuesen L, Mortensen PT, Vesterlund T, Pedersen AK (1997) Long-term follow-up of patients from a randomized trial of atrial versus ventricular pacing. Lancet 350:1210–1216PubMedCrossRefGoogle Scholar
  6. 6.
    Padeletti L, Porcioni C, Michelucci A et al (1999) Long-term efficacy in prevention of paroximal atrial fibrillation (abstract). Pacing Clin Electrophysiol 22:A14Google Scholar
  7. 7.
    Daubert G, Gras D, Leclerq C, Baisser FV, Mabo P (1995) Biatrial synchronous pacing: a new terapeutic approach to prevent refractory atrial tachyarrhythmia. J Am Coll Cardiol 25:754–761CrossRefGoogle Scholar
  8. 8.
    Boriani G, Biffi M, Padeletti L et al (1999) Consistent atrial pacing (CAP) and atrial rate stabilization (ARS): new algorithm to suppress recurrent atrial fibrillation. G Ital Cardiol 29 [Suppl 51:88–90Google Scholar
  9. 9.
    A new stimulation algorithm for suppression of atrial fibrillation: dynamic atria overdrive (DAO) (2000) DEVICE 4:1Google Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • R. M. Polimeni
    • 1
  • G. Meduri
    • 1
  • A. Amato
    • 1
  1. 1.U.O. di CardiologiaUTIC Ospedale S. Maria degli UngheresiItaly

Personalised recommendations